Exact Sciences (EXAS)
(Real Time Quote from BATS)
$70.20 USD
+0.40 (0.57%)
Updated Nov 4, 2024 09:42 AM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum D VGM
Price, Consensus and EPS Surprise
EXAS 70.20 +0.40(0.57%)
Will EXAS be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for EXAS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EXAS
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Perrigo to Report Q3 Earnings: Here's What to Expect
EXAS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Exact Sciences (EXAS) Moves to Strong Buy: Rationale Behind the Upgrade
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Will Screening Sales Drive Exact Sciences' Q3 Earnings?
Other News for EXAS
Exact Sciences price target raised to $90 from $75 at Bernstein
Exact Sciences price target raised by $15 at Bernstein, here's why
Deep Dive Into Exact Sciences Stock: Analyst Perspectives (7 Ratings)
Exact Sciences price target raised to $95 from $75 at Canaccord
Exact Sciences price target raised by $20 at Canaccord, here's why